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E-mail address: xbchen@ucdavis.edu (X. Chen).The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and
pathogenesis of various human diseases, including cancer. Although there are a large number of
E3 ubiquitin ligases, the majority are RING-ﬁnger type E3s. Pirh2, a target of p53 transcription factor,
contains a highly conserved C3H2C3 type RING domain. Importantly, Pirh2 was found to regulate a
group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc.
Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest
that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent
manner. This review will focus on the major ﬁndings in these studies and discuss the potential to
explore Pirh2 as a cancer therapeutic target.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The ubiquitin–proteasome system is one of the critical mecha-
nisms controlling protein turnover and thus maintains cellular pro-
tein homeostasis. Although protein ubiquitination is catalyzed by a
highly ordered enzymatic cascade, including ubiquitin-activating
enzyme E1s, ubiquitin-conjugating enzyme E2s, and ubiquitin
ligase E3s, the last of which primarily determine the substrate
speciﬁcity [1]. E3 ubiquitin ligases contain three major groups,
RING (the real interesting new gene) ﬁnger domain containing
E3s, HECT (the homologous to E6-AP carboxyl terminus) domain
E3s, and U-box proteins. Intriguingly, the majority of identiﬁed
E3 ubiquitin ligases contain a RING-ﬁnger domain. Evidence
showed that RING-ﬁnger E3 ubiquitin ligases target substrate pro-
teins involved in many cellular processes, such as cell proliferation,
differentiation, DNA repair, apoptosis, and metabolism [2]. As a
result, aberrant activities of RING-ﬁnger E3 ubiquitin ligases are
correlated with the pathogenesis of various human diseases,
including cancer. For example, in multiple cancers, decreased
expression of the p53 tumor suppressor is correlated with ampli-
ﬁed expression of its ubiquitin ligases, such as Mdm2 and COP1
[3,4]. Therefore, understanding how E3s are implicated in tumori-
genesis will provide clues for developing anti-E3s based cancer
therapeutics. Indeed, small molecular inhibitors of Mdm2 have
shown to be a promising treatment for tumors with elevated
Mdm2 but decreased p53 [5–7]. However, the importance of Pirh2,
a target and a ubiquitin E3 ligase of p53, in tumorigenesis islf of the Federation of European Biemerging. It appears that in addition to p53, Pirh2 regulates multi-
ple other factors, including p73, p27, PolH (DNA polymerase eta),
and c-Myc [8–12]. In this review, we will provide an overview of
current ﬁndings on Pirh2 and discuss the potential to develop
Pirh2 as a new target for cancer therapy.
2. Pirh2 and its isoforms
Human Pirh2 (p53-induced RING-H2 protein), also known as
Rchy1 (RING-ﬁnger and CHY-zinc-ﬁnger domain-containing pro-
tein 1), is encoded by the RCHY1 gene which contains nine exons
and located on the chromosome 4p21.1. To date, p53 is the only
transcription factor known to directly activate the promoter of
the RCHY1 gene [13]. Two p53 homologous, p63 and p73, share
high sequence and structure identity with p53 and regulate some
p53 target genes [14–16]. Therefore, p63 and p73 are likely to
regulate Pirh2 expression. Evidence also showed that at least ﬁve
isoforms of Pirh2 protein, named as Pirh2A, B, C, C0 (also called
Pirh2b), and D, are generated by alternative splicing (Fig. 1). Pirh2A
(full-length Pirh2) is composed of 261 amino acids and contains
the N-terminal CHY-Zn-ﬁnger domain, the central RING-ﬁnger
domain, and the C-terminal domain (CTD) (Fig. 1A). Due to alterna-
tive splicing, Pirh2B lacks exon 7, which encodes amino acids 171–
179 of the RING domain [17] (Fig. 1B). Due to the usage of a second
donor site in intron 7 and generation of a premature stop codon,
Pirh2C lacks the last seven amino acids (180–186) of the RING do-
main and the entire downstream C-terminal sequence [17]
(Fig. 1B). Due to the usage of an alternative 5’ splice site in exon
8 and a 38-nucleotide deletion in the 5’ end of exon 8 along with
a premature stop codon, Pirh2C’ contains identical amino acids toochemical Societies.
Fig. 1. Schematic representation of Pirh2 and isoforms. (A) The domains of the human Pirh2 protein and the binding sites of p53 are indicated. (B) Sequence alignment of full-
length Pirh2 and its isoforms using ClustalW2 multiple sequence alignment program. Pirh2C’ and Pirh2D have an additional unique amino acid (shown in green). (C)
Secondary sequence organization of the CHY-zinc-ﬁnger/RING-ﬁnger domain. The cysteine and histidine are labeled as C and H, respectively. There are nine potential
interleaved zinc binding sites.
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(Fig. 1B). Due to insertion of an ‘‘A’’ that shifts the reading frame
and generation of a premature stop codon, Pirh2D only contains
75 amino acids from the N-terminal of Pirh2A plus 8 unique amino
acids [19] (Fig. 1B). Pirh2 contains nine zinc binding sites, with sixin the CHY-Zn-ﬁnger domain, two in the RING domain, and one in
the CTD [20] (Fig. 1C). Since the consensus RING-H2 (C3H2C3) ﬁn-
ger domain is required for Pirh2 to act as an E3 ubiquitin ligase
in vitro and in vivo [21], Pirh2B, Pirh2C, Pirh2C’, and Pirh2D lack
the intrinsic ubiquitin ligase function because of truncation or
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Pirh2C’ are still capable of binding to p53. Interestingly, it has been
shown that Pirh2B and Pirh2C not only promote p53 ubiquitination
and degradation through Mdm2, but also inhibit p53 transcrip-
tional activity [17]. However, it is not clear how Pirh2C’ and Pirh2D
regulate p53 activity. Importantly, these alternative spliced
isoforms of Pirh2 are naturally expressed in multiple tissues.
Therefore, it is likely that all Pirh2 isoforms play a role in tumori-
genesis, but the mechanism needs to be further explored.
3. The binding partners and potential substrates/targets of
Pirh2
Pirh2 was originally identiﬁed as an androgen receptor (AR) N-
terminal interacting protein (ARNIP) [21], suggesting that Pirh2 is
involved in the AR signaling pathway. Indeed, Pirh2 was found to
enhance the recruitment of AR to the promoter of the PSA (prostate
speciﬁc antigen) gene or promote the degradation of AR corepres-
sor HDAC1 (histone deacetylase 1) [22]. In addition, Pirh2 is also
found to inhibit androgen-dependent secretion of PSA via ubiquiti-
nation and degradation of e-COP (e-subunit of coatmer complex)
[23]. These indicate that Pirh2 might promote prostate cancer
formation. The oncogenic activity of Pirh2 is consistent with the
ﬁndings that Pirh2 ubiquitinates and degrades multiple tumor sup-
pressors, including p53, p73, and p27 [9,12,13,20]. By contrast,
Hakem et al., showed that the c-Myc oncoprotein is a new Pirh2
binding partner and degraded by Pirh2-mediated polyubiquitina-
tion [8]. Meanwhile, it was found that Pirh2/ mice with elevated
expression of c-Myc are predisposed to plasma cell hyperplasia and
tumorigenesis, which is further enhanced by p53-deﬁciency [8].
Together, Pirh2 might play a role in cell cycle progression via reg-
ulating checkpoint proteins and disrupting the balance between
pro- and anti-cell proliferation activities of Pirh2 contributes to tu-
mor formation in a tissue-speciﬁc manner.
To date, Pirh2 has been shown to associatewithwell over 20 pro-
teins: some are Pirh2 targets and others are Pirh2 regulators (Table
1). For examples, histone acetyltransferase Tip60 (Tat-interactive
protein of 60 kDa) and PLAGL2 (pleomorphic adenoma gene like 2)
[24,25] inhibit auto-ubiquitination and degradation of Pirh2 [17].
In addition, Pirh2 can enhance Mdm2 expression by interactingTable 1
Reported Pirh2-binding partners.
Protein Function
AIG1 Activates NFAT signaling pathway [68]
AR Mediates androgen signaling in prostate dev
ARF4 Stimulates the ADP-ribosyltransferase activit
Axin Acts as a tumor suppressor and a negative re
CaMKII Serine/threonine-speciﬁc protein kinase that
c-Myc An oncogenic transcription factor that is acti
COP1 A negative regulator of p53 [28]
PolH A DNA polymerase involved in DNA repair b
e-COP A subunit of COPI coatomer complex that is
HDAC1 A histone deacetyltransferase that is respons
K8/18 A major components of intermediate ﬁlamen
Mdm2 A major negative regulator of p53 [28]
Mdmx A enzymatically inactive component of Mdm
MV P Contributes to innate immune evasion [72]
PCV2 ORF3 Induces apoptosis and regulates p53 ubiquit
p27 Inhibits G1–S transition [9]
p53 A tumor suppressor [13,20]
p73 A member of p53-superfamily proteins [12,6
PLAGL2 Acts as a transcription factor and suppresses
SCYL1-BP1 A member of the Golgin family which is invo
SRb A docking protein that is involved in targetin
Tip60 A histone acetyltransferase that has a role in
AIG1, androgen induced gene 1; AR, androgen receptor; ARF4, ADP-ribosylation factor
PolH, DNA polymerase eta; HDAC1, histone deacetylase 1; Mdm2, murine double minute
adenoma gene like 2; SCYL1-BP1, SCY1-like 1 binding protein 1; SRb, signal recognitionwith SCYL1-BP1 (SCY1-like 1 binding protein 1), a regulator of
Mdm2 auto-ubiquitination [26,27]. Moreover, Pirh2 can be
increased by Mdm2 and COP1 coexpression [28], although the
mechanism is not clear. Interestingly, we have showed that Pirh2
associates with and promotes ubiquitin-independent 20S proteaso-
mal degradation of PolH, a Y-family translesion DNA polymerase re-
quired for bypassing UV-induced DNA damage [11]. In addition, we
showed that Pirh2 monoubiquitinates PolH, which blocks PolH
association with PCNA and prevents PolH from bypassing UV-in-
duced DNA lesions [10].
Additionally, there exist a few potential target proteins for
Pirh2. First, p21 might be regulated by Pirh2. Previously, we
showed that p21 is increased by Pirh2 knockdown, whereas
decreased by Pirh2 overexpression in H1299 cells [11]. Since
p21 degradation is regulated by several E3 ubiquitin ligases
[29], the relationship among which needs to be further investi-
gated. Second, p63 is a potential target protein for Pirh2-medi-
ated degradation. p53, p63, and p73 share high structural
similarity and can form mixed tetramers [30–32]. Since Pirh2
promotes degradation of p53 and p73, it is likely that Pirh2 reg-
ulates p63 stability.
4. The role of Pirh2 in the p53-Mdm2 axis
Mdm2, a RING-ﬁnger domain E3 ligase, is the ﬁrst identiﬁed
non-viral E3 ligase degrading p53 via the ubiquitin–proteasome
system [33–37]. In addition, Mdm2 is also capable of regulating
its own levels through auto-polyubiquitination [38]. As a transcrip-
tional target of p53, Mdm2 acts as a negative feedback regulator of
p53 to maintain low levels of p53 expression [39,40]. In addition to
polyubiquitinating p53, Mdm2 mediates p53 monoubiquitination
leading to nuclear export of p53 [41]. However, Mdm2 loses its
biological activity to regulate p53 upon DNA damage. On the one
hand, DNA damage-induced Mdm2 phosphorylation at Ser-395
disrupts Mdm2 interaction with p53 due to its conformational
change [42]. On the other hand, DNA damage-induced phosphory-
lation of p53 at Ser-15 and Ser-20 dissociates p53 from Mdm2
[43,44]. Therefore, the p53-Mdm2 regulatory loop has been
proposed to be a critical mechanism for degrading p53 in an
unstressed condition (Fig. 2).Substrate
n.d.
elopment and differentiation [21,22] No
y [69] n.d.
gulator of Wnt-signaling [45] No
is regulated by calmodulin complex [70] No
vated by mitogenic signals [8] Yes
n.d.
y translesion synthesis [10,11] Yes
involved in Golgi-trafﬁcking [23] Yes
ible for the deacetylation of histone [22] Yes
ts in single layer epithelial cells [71] No
n.d.






cellular differentiation [25] n.d.
lved in the secretary pathway [26,27] Yes
g secretary protein to ER [75] Yes
the DNA damage response [24] n.d.
4; CaMKII, calmodulin kinase II; COP1, constitutive photomorphogenesis protein1;
2; PCV2 ORF3, porcine circovirus type 2 open reading frame 3; PLAGL2, pleomorphic
particle receptor b; Tip60, tat-interactive protein of 60 kDa.
Fig. 2. A model for the biological role of Pirh2 in the p53-Mdm2 axis. Under normal conditions, p53 is associated with Pirh2 and Mdm2 and thereby degraded by the 26S
proteasome. Upon stresses, Mdm2 is released from p53, whereas Pirh2 become a primary negative regulator of p53.
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dation (Fig. 2). Like Mdm2, Pirh2 is a transcriptional target of p53
and can degrade p53 protein through the proteasomal degradation
pathway [13,20]. Thus, p53 and Pirh2 constitute a negative regula-
tory feedback loop. Unlike Mdm2, Pirh2 is able to downregulate
p53 in response to DNA damage. It has been shown that upon mod-
erate DNA damage, Pirh2 suppresses Axin-HIPK2-mediated p53
phosphorylation at Ser-46 by competing with HIPK2 for binding
to Axin, and thus inhibits p53-mediated apoptosis [45]. However,
upon lethal DNA damage, Tip60 competes with and dissociates
Pirh2 from Axin, and consequently, the assembly of Axin-Tip60-
HIPK2-p53 protein complex induces p53-mediated apoptosis
[45]. In addition, Pirh2/ mice display enhanced p53 expression
and DNA damage response [8]. Together, these suggest that Pirh2
acts as a negative regulator of p53 in both unstressed and stressed
conditions. As mentioned above, Pirh2 isoforms lacking the RING
domain are still able to degrade p53. Therefore, whether Pirh2-
mediated ubiquitination is essential for p53 degradation and
whether other factors are implicated in the p53-Pirh2 feedback
loop need to be further investigated.
Similar to Mdm2 and Pirh2, COP1 (constitutively photomorph-
ogenic 1), a p53 target, is a RING-ﬁnger E3 ligase that targets p53
for degradation [46]. It has been shown that Mdm2, Pirh2, and
COP1 are capable of forming a dimer and mutually enhance their
protein stability [28]. In addition, COP1 coordinates with Mdm2
and Pirh2 to enhance p53 degradation [46]. Thus, a proper level
of p53 is ensured by a set of E3 ligases. Interestingly, p73 turnover
is regulated by Pirh2, but not by Mdm2 and COP1 [47–49]. This
suggests that Pirh2 also regulates its own substrates different from
Mdm2 and COP1. However, whether Mdm2 and COP1 modulate
the ability of Pirh2 to target Pirh2-speciﬁc substrates needs to be
further investigated.
5. Pirh2 as a novel anticancer target
Pirh2 expression was found to be upregulated in multiple can-
cers, including lung, prostate, head and neck cancers, and hepato-
cellular carcinoma [22,50–52], indicating that Pirh2 mightpromote tumor formation. However, the view that Pirh2 acts as
an oncogene has been challenged by the ﬁnding that Pirh2 exhibits
tumor suppression activity in some types of cancer via degrading
the c-Myc oncoprotein [8]. In addition, reduced expression of Pirh2
in several human cancers, such as lung, ovarian, breast, and blad-
der cancers, is correlated with poor survival [8,53–56]. Therefore,
Pirh2 might serve as a novel prognostic biomarker for speciﬁc
types of cancers.
Small molecule compounds, such as Nutlin-3a, RITA, and MI-
219, have been identiﬁed as potent Mdm2 inhibitors [5–7]. These
small molecule compounds disrupt Mdm2-mediated p53 degrada-
tion and thus lead to tumor regression by inducing p53-mediated
cell cycle arrest and cell death [5,7,57]. However, these small
molecules are not effective in some cases [58–60]. Similar to
Mdm2, Pirh2 is a negative regulator for p53. Thus, small molecule
compounds targeting Pirh2 might provide a solution for cancers
resistant to Mdm2 inhibitors. In addition to Mdm2-like activities,
Pirh2 regulates its own targets. For instance, high Pirh2 and low
p27 have been observed in several cancers [9,52]. Since p27 inhib-
its the G1/S progression in a p53-independent manner, activation
of p27 by inhibiting Pirh2 would be an alternative approach to
treat cancers deﬁcient in p53. Similarly, p73, a p53 family member,
exerts tumor suppressor activity in tumors lacking p53 [61,62]. We
and others showed that Pirh2 promotes p73 polyubiquitination
and degradation [12,63]. Thus, it is likely that activation of p73 is
another therapeutic strategy in the absence of p53. In addition,
we showed that Pirh2 is a major factor that inhibits PolH activity
in TLS (translesion DNA synthesis) [10,11]. Since downregulation
of PolH is known to predispose XPV patients to UV-induced skin
cancers [64,65], selective small molecule inhibitors targeting the
Pirh2-PolH loop may be explored for malignancies associated with
PolH deﬁciency. However, low Pirh2 was correlated with c-Myc
activation in certain types of cancers. Since induction of cell death
and/or cellular senescence upon c-Myc inactivation leads to regres-
sion of some tumors lacking functional p53 [8,66], small molecules
activating Pirh2 may be feasible for c-Myc-based cancer therapy.
Nevertheless, Pirh2-targeting molecules may provide a useful tool
to uncover how Pirh2 promotes and inhibits tumorigenesis and
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Pirh2-overexpressing/deﬁcient tumors.
6. Concluding remarks
The ubiquitin proteasome pathway plays a critical role in regu-
lating many signaling pathways important for cancer cell growth
and survival. Inhibition of proteasome function has been postu-
lated to be a new direction for developing anti-cancer drugs. The
feasibility of this hypothesis was approved by preclinical studies
on a proteasome inhibitor Bortezomib [67]. However, much work
is needed to improve the speciﬁcity and efﬁciency of proteasome
inhibitors. Since the speciﬁcity of the ubiquitin proteasome path-
way is primarily determined by E3 ligases, developing E3 ligase
inhibitors would be one solution to improve pharmacological
properties of proteasome inhibitors. For example, Nutlin-3a, a
small molecule that interrupts Mdm2-mediated p53 ubiquitina-
tion and degradation, is one potential drug to treat cancers with
increased Mdm2 and decreased p53. However, it is not applicable
to all cancers especially tumors with mutant p53. Thus, it is neces-
sary to identify new targets. Evidence showed that expression lev-
els of Pirh2 are altered in various human cancers. Along with this,
evidence showed that Pirh2 regulates a growing number of key
factors for cell survival and cell death, including p53, p73, p27,
PolH, and c-Myc. Therefore, Pirh2 may be explored as a target for
cancer therapeutics. However, there are several issues remained
to be answered. For example, how does Pirh2 exert two opposing
cellular functions as an oncoprotein or a tumor suppressor in dif-
ferent tissues? Are there other regulators or targets of Pirh2 in
tumorigenesis? How is p53 activity affected by the elevated Pirh2
in breast and lung cancers? Does Pirh2:p53 dysregulation repre-
sent a new mechanism for cellular transformation in certain types
of cancers? Do Pirh2 isoforms directly or indirectly regulate Pirh2
substrates by interfering with Pirh2 function? Does Pirh2 exert E3
ubiquitin ligase-independent activities? Addressing these ques-
tions will facilitate our understanding of Pirh2 functions and
provide a foundation for developing Pirh2-based cancer therapies.
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